GynecologyGynecologyГинекология2079-56962079-5831Consilium Medicum28472ArticlesСтатьиResearch ArticleNew features in the diagnosis of "lesser" abnormalities of cervical epithelium associated with HPV infection (review of literature)Новые возможности диагностики «малых» форм поражений эпителия шейки матки, ассоциированных с папилломавирусной инфекцией (обзор литературы)NazarovaN MНазароваН МPrilepskayaV NПрилепскаяВ НVPrilepskaya@mail.ruSychevaE GСычеваЕ ГZardiashviliM DЗардиашвилиМ ДBourmenskayaO VБурменскаяО ВV.I.Kulakov Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian FederationФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России15102015175VOL 17, NO5 (2015)ТОМ 17, №5 (2015)323609042020Copyright ©; 2015, Consilium MedicumCopyright ©; 2015, ООО "Консилиум Медикум"2015Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://gynecology.orscience.ru/2079-5831/article/view/28472

In this review we observed the role of high risk HPV types in the development of epithelial lesions of the cervix. Modern data on the role of molecular genetic methods in the diagnosis of HPV-associated diseases are represented here. We analyze the literature on modern molecular biomarkers that shows the risk of proliferative processes in the transformation to neoplasia.

В обзоре рассмотрена роль высокоонкогенных типов вируса папилломы человека (ВПЧ) в развитии поражений эпителия шейки матки. Представлены современные данные о роли молекулярно-генетических методов исследования в диагностике ВПЧ-ассоциированных заболеваний. Анализируется литература о современных молекулярных биомаркерах, которые отражают риск развития пролиферативных процессов с переходом в неоплазии.

human papillomaviruscervical intraepithelial neoplasiacervixmolecular genetic markersE6/E7 mRNAвирус папилломы человекацервикальные интраэпителиальные неоплазиишейка маткимолекулярно-генетические маркерымРНК Е6/Е7Золотоверхая Е.А. Молекулярные маркеры онкогенной активности вируса папилломы человека: Автореф. дис. ... канд. мед. наук. Спб, 2009.Lehtinen M. Интеграция вакцины против вирусов папилломы человека в национальные программы иммунизации. Европейский журн. по секс. и репрод. здоровью. 2007; 64: 12.Waxman A.G, Chelmow D, Darragh T.M et al. Revised Terminology for Cervical Histopathology and Its Implications for Management of High-Grade Squamous Intraepithelial Lesions of the Cervix. Obstet Gynecol 2012; 120 (6): 1465-71.Doorbar J, Egawa N, Griffin H. Human papillomavirus molecular biology and disease association. Rev Med Virol 2015; 25: 2-23.Cricca M, Morselli-Labate A.M, Venturoli S et al. Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high - grade cervical lesions. Gynecol Oncol Res 2007; 106 (3): 49-57.Lethaby A, Brown J, Marjoribanks et al. Phytoestrogens for vasomotor menopausal symptoms. Cochran Database Syst Rev 2007: CD001395Куевда Д.А., Шипулина О.Ю. Генодиагностика папилломавирусной инфекции высокого канцерогенного риска. Количественный подход. Патология шейки матки и генитальная инфекция. Т. 3. М., 2007; c. 108-19.Kapeu A.S, Luostarinen T, Jellum E et al. Is Smoking an Independent Risk Factor for Invasive Cervical Cancer? A Nested Case-Control Study Within Nordic Biobanks. Am J Epidemiol 2009; 169 (4): 480-8.Sørbye S.W, Fismen S, Gutteberg T.J et al. Triage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing. PLoS One 2010; 5 (9): e12724.Ghittoni R, Accardi R, Chiocca S et al. Role of human papillomaviruses in carcinogenesis. ecancer 2015, 9: 526.Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2 (5): 342-50.Bosch F.X et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group [see comments] J Natl Cancer Inst 1995; 87 (11): 796-802.Munoz N et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348 (6): 518-27.De Sanjose S et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective crosssectional worldwide study. Lancet Oncol 2010; 11 (11): 1048-56.Smith J.S et al. Human papillomavirus type distribution in invasive cervical cancer and high - grade cervical lesions: a meta - analysis update Int J Cancer 2007; 121 (3): 621-32.von Knebel-Döberitz M, Syrjänen K. Molecular markers. How to apply in practice. Gynecol Oncol 2006; 103: 18-20.Szoke K, Sapy T, Krasznai Z et al. Moderate variation of the oncogenic potential among high - risk human papillomavirus types in gynecologic patients with cervical abnormalities. J Med Virol 2003; 71: 585-92.Molano M, van den Brulel A, Plummer M et al. Determinants of Clearance of Human Papillomavirus Infections in Colombian Women with Normal Cytology: A Population - based, 5-Year Follow - up Study. Am J Epidemiol 2003; 158 (5): 486-94.Schneider A et al. Screening for cervical intraepithelial neoplasia grade 2/3: validity of cytologic study, cervicography, and human papillomavirus detection. Am J Obstet Gynecol 1996; 174 (5): 1534-41.Grce M, Davies P. Human papillomavirus testing for primary cervical cancer screening. Expert Rev Mol Diagn 2008; 8 (5): 599-605.Mandelblatt J.S, Lawrence W.F, Womack S.M et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002; 287: 2372-81.Naucler P, Ryd W, Törnberg S et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-97.Schiffman M, Wentzensen N. From Human papillomavirus to cervical cancer. Obstet Gynecol 2010; 116 (1): 177-85.Sorbye S.W, Fismen S, Gutteberg T.J et al. HPV mRNA test in women with minor cervical lesions: experience of the University Hospital of North Norway. J Virol Methods 2010; 169: 219-2.Tropé A, Sjoborg K, Eskild A et al. Performance of Human Papillomavirus DNA and mRNA Testing Strategies for Women with and without Cervical Neoplasia. J Clin Microbiol 2009; 47 (8): 2458-64.Castle P.E, Fetterman B, Poitras N et al. Variable risk of cervical precancer and cancer after a human papillomavirus - positive test. Obstet Gynecol 2011; V (117); 650-6.Ho G.Y, Bierman R, Beardsley L et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423-28.Sankaranarayanan R et al. HPV screening for cervical cancer in rural India N Engl J Med 2009; 360 (14): 1385-94.Tropé A, Sjoborg K.D, Nygård M et al. Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high - grade cervical neoplasia between screening rounds. J Clin Microbiol 2012; 50 (6): 1927-35.Ronco G, Cuzick J, Pierotti P et al. Accuracy of liquid versus conventional cytology: overall results of new technologies for cervical cancer screening: randomized controlled trial. BMJ 2007; 335 (7609): 28.Moore E.E, Danielewski J.A, Garland S.M et al. Clearance of human papillomavirus in women treated for cervical dysplasia. Obstet Gynecol 2011; 117: 101-8.Серов В.Н., Баранов И.И. Лечение урогенитальных инфекций у женщин в современных условиях. Рус. мед. журн. 2004; 12 (8): 564-9.Шабалова И.П., Касоян К.Т. Цитологическая диагностика заболеваний шейки матки и тела матки. 3-е изд., испр. и доп. М.: Триада, 2010.Ronco G, Cuzick J, Pierotti P et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening randomized controlled trial. BMJ 2007; 5 (7609): 28-38.Роговская С.И. Папилломавирусная инфекция у женщин и патология шейки матки: в помощь практикующему врачу. М.: ГЭОТАР-Медиа, 2005; 39-42.Троицкая О.Г. Современные методы диагностики и лечения папилломавирусной инфекции шейки матки у женщин репродуктивного возраста. Автореф. дис. … канд. мед. наук. Спб., 2008.Arbyn M, Martin-Hirsch P, Buntinx F et al. Triage of women with equivocal or low - grade cervical cytology results: a meta - analysis of the HPV test positivity rate. J Cell Mol Med 2009; 13: 648-59.Koliopoulos G, Arbyn M, Martin-Hirsch P et al. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta - analysis of non - randomized studies. Gynecol Oncol 2007; 104 (1): 232-46.Сухих Г.Т., Прилепская В.Н. Профилактика рака шейки матки. М.: МЕДпресс - информ, 2012; с. 25-30.Роговская С.И., Подзолкова Н.М., Минкина Г.Н. Новое в кольпоскопии. Гинекология. 2011; 13 (5): 62-6.Saslow D, Castle P.E, Cox J.T et al. American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors. C A Cancer J Clin 2007; 57: 7-28.Wentzensen N, Sherman M.E, Schiffman M et al. Utility of methylation markers in cervical cancer early detection: appraisal of the state - of - the - science. Gynecologic Oncology 2009; 112 (2): 293-9.Nasioutziki M, Daniilidis A, Dinas K et al. The evaluation of p16INK4a immunoexpression/immunostaining and human papillomavirus DNA test in cervical liquid - based cytological samples. Int J Gynecol Cancer 2011; 21 (1): 79-85.Sørbye S.W, Fismen S, Gutteberg T.J et al. HPV mRNA Is More Specific than HPV DNA in Triage of Women with Minor Cervical Lesions. PLoS One 2014; 9 (1).Wang F, Li Y, Zhou J et al. miR-375 is down - regulated in squa - mous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. Am J Pathol 2011; 179: 2580-8.Caraceni D, Ghiringhello B, Keller T et al. p16/ki-67 dual - stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol 2011; 119 (3): 158-66.Possati-Resende J.C, Fregnani J.H, Kerr L.M et al. The Accuracy of p16/Ki-67 and HPV Test in the Detection of CIN2/3 in Women Diagnosed with ASC-US or LSIL. PLoS One 2015; 10 (7).Heng Z.M, Wang X. Regulation of cellular miRNA expression by human papillomaviruses. Biochim Biophys Acta 2011; 1809 (11-12): 668-77.Molden T, Nygård J.F, Kraus I et al. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-Proofer and consensus PCR: a 2-year follow - up of women with ASCUS or LSIL Pap smear. Int J Cancer 2005; 114 (6): 973-6.Cuzick J, Cadman L, Mesher D et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer 2013; 108: 908-13.Cattani P, Zannoni G.F, Ricci C et al. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high - grade lesions of the cervix. J Clin Microbiol 2009; 47: 3895-01.